WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO aims at promoting scientific excellence in fundamental life sciences research and translating scientific achievements in medical, pharmaceutical and veterinary biotechnology applications.
Researchers from the Université libre de Bruxelles, led by Cédric Blanpain (WELBIO investigator) and a team for the University of Cambridge (led by Berthold Göttgens), identified the role of key gene Mesp1 in the earliest step of cardiovascular lineage segregation. The results of this discovery that may help to better understand congenital heart defects, have been published in Science.
Bacteria must sense and respond to changes in their environment to survive, and their exterior membranes are their first line of defense. Exciting new research reveals a previously unappreciated aspect of this defense, which could be exploited to render antibiotic-resistant bacteria beatable. The research was led by Jean-François Collet, WELBIO investigator at UCLouvain's de Duve Institute in Belgium and colleagues from the University of Utah and Imperial College London. This potentially opens the door to promising new treatments. The results of this study have been published in Plos Biology.
Immunotherapy generated undreamt-of results in the treatment of aggressive and advanced metastatic cancer. But it occurred only one-fourth to one-third of patients are responding positively, leaving a large majority that didn’t respond to immunotherapy. Explaining why and increasing immunotherapy’s efficiency were the research objectives of Benoît Van den Eynde, WELBIO investigator at UCL’s de Duve Institute and director of the Brussels Branch of the Ludwig Cancer Research Institute. The results of this study were published in Nature Communications.